Join Growin Stock Community!

Reviva pharmaceuticals holdings, inc.RVPH.US Overview

US StockHealthcare
(No presentation for RVPH)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RVPH AI Insights

RVPH Overall Performance

RVPH AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RVPH Recent Performance

8.29%

Reviva pharmaceuticals holdings, inc.

0.05%

Avg of Sector

-0.31%

S&P500

RVPH PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RVPH Key Information

RVPH Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RVPH Profile

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.

Price of RVPH

RVPH FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RVPH Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.51
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.51
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is RVPH's latest earnings report released?

    The most recent financial report for Reviva pharmaceuticals holdings, inc. (RVPH) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RVPH's short-term business performance and financial health. For the latest updates on RVPH's earnings releases, visit this page regularly.

  • How much cash does RVPH have?

    At the end of the period, Reviva pharmaceuticals holdings, inc. (RVPH) held Total Cash and Cash Equivalents of 13.18M, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is RVPH's EPS continuing to grow?

    According to the past four quarterly reports, Reviva pharmaceuticals holdings, inc. (RVPH)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RVPH?

    Reviva pharmaceuticals holdings, inc. (RVPH)'s Free Cash Flow (FCF) for the period is -5.59M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 31.78% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.